Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) Enterprise Value (2020 - 2026)

Addex Therapeutics' Enterprise Value history spans 8 years, with the latest figure at -$2.1 million for Q4 2025.

  • On a quarterly basis, Enterprise Value rose 46.19% to -$2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 46.19% increase, with the full-year FY2025 number at -$2.0 million, up 48.13% from a year prior.
  • Enterprise Value came in at -$2.1 million for Q4 2025, up from -$2.7 million in the prior quarter.
  • The five-year high for Enterprise Value was -$490.17 in Q3 2023, with the low at -$22.2 million in Q4 2021.
  • Historically, Enterprise Value has averaged -$9.2 million across 5 years, with a median of -$4.3 million in 2023.
  • Biggest five-year swings in Enterprise Value: soared 100.0% in 2023 and later tumbled 47908.68% in 2025.
  • Year by year, Enterprise Value stood at -$22.2 million in 2021, then soared by 67.51% to -$7.2 million in 2022, then surged by 39.67% to -$4.4 million in 2023, then increased by 12.31% to -$3.8 million in 2024, then skyrocketed by 46.19% to -$2.1 million in 2025.
  • Business Quant data shows Enterprise Value for ADXN at -$2.1 million in Q4 2025, -$2.7 million in Q3 2025, and -$2.8 million in Q2 2025.